首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas.
【24h】

Clinical implication of screening p53 gene mutations in head and neck squamous cell carcinomas.

机译:在头颈部鳞状细胞癌中筛选p53基因突变的临床意义。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The role of the tumour-suppressor gene p53 in the tumorigenesis of head and neck cancer has been well established, but the clinical significance of p53 alteration is still unclear. A group of 50 patients with head and neck squamous cell carcinoma (HNSCC) were investigated for p53 alterations. DNA was extracted from fresh tumour samples and polymerase chain reaction/single-strand conformation polymorphism analysis was used to detect p53 gene mutations in the region from exon 5 to exon 9. In addition, p53 protein overexpression was assessed by immunohistochemistry using the monoclonal antibody DO-7 on paraffin-embedded tissue sections. p53 gene mutations were found in 45% and p53 protein expression was detected in 61.2% of tumour samples. While p53 protein expression was not correlated with any clinical factors, p53 gene mutations indicated local regional recurrences of HNSCC. The risk of locoregional recurrence was significantly greater in patients with a p53 gene mutation than in patients with the wild-type p53 gene (P = 0.001). Multivariate analysis confirmed p53 gene mutation to be an independently predictive factor for the tumour recurrence (P = 0.0064). When we analysed p53 gene mutation in 12 patients with primary and recurrent tumours, we found that 4 patients (33.3%) had a different p53 gene mutation in the recurrent tumour from that in the original primary tumour. The results indicate that p53 gene mutations and not protein overexpression are valuable predictors for tumour recurrences and for differential diagnosis of a second primary HNSCC.
机译:肿瘤抑制基因p53在头颈癌的肿瘤发生中的作用已被很好地确立,但p53改变的临床意义仍不清楚。研究了一组50例头颈部鳞状细胞癌(HNSCC)患者的p53改变。从新鲜肿瘤样品中提取DNA,并使用聚合酶链反应/单链构象多态性分析检测外显子5至外显子9区域的p53基因突变。此外,使用单克隆抗体DO通过免疫组织化学评估p53蛋白的过表达-7在石蜡包埋的组织切片上。在45%的肿瘤样本中发现p53基因突变,在61.2%的肿瘤样本中检测到p53蛋白表达。虽然p53蛋白表达与任何临床因素均不相关,但p53基因突变表明HNSCC局部复发。具有p53基因突变的患者局部复发的风险显着高于具有野生型p53基因的患者(P = 0.001)。多变量分析证实p53基因突变是肿瘤复发的独立预测因素(P = 0.0064)。当我们分析12例原发性和复发性肿瘤患者的p53基因突变时,我们发现4例(33.3%)的复发性肿瘤中p53基因突变与原始原发性肿瘤不同。结果表明,p53基因突变而非蛋白过表达是肿瘤复发和第二原发性HNSCC鉴别诊断的重要预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号